The mortality rate for cervix uteri malignant neoplasms in the UK shows a slight upward trend from 872 female deaths in 2024 to 878 in 2028. Compared to 2023, the annual mortality rate indicates a stable yet incrementally increasing pattern. The year-on-year growth rate remains minimal, suggesting a consistent rise, albeit at a slow pace. The compound annual growth rate (CAGR) over the five-year period reflects this steady increase.
Future trends to watch for include the potential impact of improved screening programs, HPV vaccinations, and advancements in treatment methods, which could alter the trajectory of mortality rates, possibly stabilizing or even reducing them over time.
